沙立度胺联合MP化疗方案治疗多发性骨髓瘤23例

目的：观察沙立度胺联合MP方案治疗多发性骨髓瘤的疗效及其不良反应。方法：确诊的多发性骨髓瘤患者23例。沙立度胺-MP方案：沙立度胺自MP方案开始持续给药，每晚睡前口服，剂量从每天100mg开始，每周日剂量递增50mg，至患者不能耐受或最高至每日400mg；MP方案每月1个疗程。结果：部分缓解16例（69．6％），进步4例（17．4％），总有效率为87．0％（20／23）。有效的患者中10例在4周内起效，沙立度胺每天100～400mg，中位剂量每天225mg。常见的不良反应为皮疹、便秘、嗜睡、乏力、头昏、水肿等。结论：沙立度胺加MP方案治疗多发性骨髓瘤不良反应少，耐受性好，且反应率可能提高。

Clinical efficacy of thalidomide with melphalan and prednison in the treatment of 23 cases multiple myeloma

Objective:To report the preliminary result of therapy with thalidomide in 23 cases of multiple myeloma(MM) patients.Method:The initial dose of thalidomide was 100 mg/d, then increased 50 mg/d to 400 mg/d every week until the patient's maximal tolerance. Chemotherapy with melphalan 0.1 mg/kg daily and oral prednison 1.0 mg/kg daily for seven days was accompanied in all patients.Result:Among the 23 patients 16 achieved partial remission (PR), 4 improved and 3 had no effect.Conclusion:Thalidomide can be used in the treatment of MM. Side effects was tolerable.